Organogenesis - Public Comps and Valuation Multiples

Organogenesis Overview

About Organogenesis

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Founded

2018

HQ

Employees

869

Website

organogenesis.com

Sectors

Regenerative Medicine
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $484M

LTM EBITDA $41.8M

EV

$616M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Organogenesis Financials

As of August 2025, Organogenesis reported last 12-month revenue of $484M and EBITDA of $41.8M.

In the same period, Organogenesis generated $361M in LTM gross profit and -$4.3M in net income.

See Organogenesis valuation multiples based on analyst estimates

Organogenesis P&L

In the most recent fiscal year, Organogenesis reported revenue of $482M and EBITDA of $15.8M.

Organogenesis expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Organogenesis valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$484M	XXX	$482M	XXX	XXX	XXX
Gross Profit	$361M	XXX	$366M	XXX	XXX	XXX
Gross Margin	75%	XXX	76%	XXX	XXX	XXX
EBITDA	$41.8M	XXX	$15.8M	XXX	XXX	XXX
EBITDA Margin	9%	XXX	3%	XXX	XXX	XXX
EBIT	-$3.6M	XXX	$21.5M	XXX	XXX	XXX
EBIT Margin	-1%	XXX	4%	XXX	XXX	XXX
Net Profit	-$4.3M	XXX	$0.9M	XXX	XXX	XXX
Net Margin	-1%	XXX	0%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Organogenesis including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $484M. EBITDA for the last twelve months was $41.8M. In the most recent fiscal year, Organogenesis achieved $482M in revenue and $15.8M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$484M	Analyst estimates available to subscribers	$482M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$361M	Analyst estimates available to subscribers	$366M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	74.7% gross margin	Analyst estimates available to subscribers	76.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$41.8M	Analyst estimates available to subscribers	$15.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	8.6% EBITDA margin	Analyst estimates available to subscribers	3.3% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$3.6M	Analyst estimates available to subscribers	$21.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-0.7% EBIT margin	Analyst estimates available to subscribers	4.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$4.3M	Analyst estimates available to subscribers	$0.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-0.9% net profit margin	Analyst estimates available to subscribers	0.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Organogenesis

This financial data table provides comprehensive performance metrics for Organogenesis, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Organogenesis generated $484M in revenue over the last twelve months.
The company achieved $41.8M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $361M.
Net income over the last twelve months reached -$4.3M.

Fiscal Year Performance

In the most recent fiscal year, Organogenesis reported $482M in total revenue.
Fiscal year EBITDA was $15.8M.
The company maintained a gross profit margin of 76.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 3.3%.
Net profit margin reached 0.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Organogenesis. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Organogenesis Stock Performance

Organogenesis has current market cap of $520M, and EV of $616M.

Market Cap Evolution

Organogenesis Stock Data

As of September 30, 2025, Organogenesis's stock price is $4.

See Organogenesis trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$616M	$520M	XXX	XXX	XXX	XXX	$0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Organogenesis Valuation Multiples

Organogenesis's trades at 1.3x EV/Revenue multiple, and 39.1x EV/EBITDA.

See valuation multiples for Organogenesis and 15K+ public comps

Organogenesis Financial Valuation Multiples

As of September 30, 2025, Organogenesis has market cap of $520M and EV of $616M.

Equity research analysts estimate Organogenesis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Organogenesis has a P/E ratio of -119.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$520M	XXX	$520M	XXX	XXX	XXX
EV (current)	$616M	XXX	$616M	XXX	XXX	XXX
EV/Revenue	1.3x	XXX	1.3x	XXX	XXX	XXX
EV/EBITDA	14.7x	XXX	39.1x	XXX	XXX	XXX
EV/EBIT	-172.0x	XXX	28.6x	XXX	XXX	XXX
EV/Gross Profit	1.7x	XXX	n/a	XXX	XXX	XXX
P/E	-119.6x	XXX	604.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	147.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Organogenesis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Organogenesis Margins & Growth Rates

Organogenesis's last 12 month revenue growth is 19%

Organogenesis's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.4M for the same period.

Organogenesis's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Organogenesis's rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Organogenesis and other 15K+ public comps

Organogenesis Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	19%	XXX	12%	XXX	XXX	XXX
EBITDA Margin	9%	XXX	3%	XXX	XXX	XXX
EBITDA Growth	30%	XXX	4%	XXX	XXX	XXX
Rule of 40	28%	XXX	22%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	57%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.6M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	10%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	72%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial